4.7 Review

Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review

期刊

JOURNAL OF AFFECTIVE DISORDERS
卷 311, 期 -, 页码 69-77

出版社

ELSEVIER
DOI: 10.1016/j.jad.2022.05.017

关键词

Bipolar disorder; Rapid cycling; Treatment

向作者/读者索取更多资源

This paper provides an overview of evidence-based treatment options for rapid cycling in bipolar disorder, highlighting medications such as aripiprazole, olanzapine, quetiapine, valproate, and lamotrigine. However, evidence regarding the treatment of rapid cycling remains scarce, indicating the need for future research to further validate the efficacy of these treatment methods.
Objectives: Rapid cycling is a phase of bipolar disorder with increased episode frequencies. It is a severe and disabling condition that often poses a major challenge to the clinician. The aim of this paper is to give an overview of the evidence-based treatment options for rapid cycling.Methods: A systematic search on Pubmed, Embase and Cochrane databases from inception until December 2021 was conducted according to the PRISMA guidelines. An additional search on clinicaltrials.gov was done. References of retrieved papers and key reviews were hand-searched. Randomized controlled trials including at least 10 patients with bipolar disorder, rapid cycling, reporting an objective outcome measure were selected.Results: Our search, initially revealing 1330 articles, resulted in 16 papers about treatment of an acute mood episode, relapse prevention or both. Lithium, anticonvulsants, second generation antipsychotics, antidepressants and thyroid hormone were assessed as treatment options in the presented data. Evidence supporting the use of aripiprazole, olanzapine, quetiapine, valproate and lamotrigine for treatment of rapid cycling bipolar disorder was found. Limitations: Small sample sizes, different index episodes and variety of outcome measures.Conclusion: Evidence regarding treatment of rapid cycling remains scarce. Evidence supports the use of aripiprazole, olanzapine, and valproate for acute manic or mixed episodes, quetiapine for acute depressive episodes and aripiprazole and lamotrigine for relapse prevention. Given the paucity of available evidence, and the burden that accompanies rapid cycling, future research is warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据